National Research Corp

National Research Corp. engages in the provision of analytics and insights that facilitate patient, employee, and customer retention. It offers solutions that address specific needs around market insight, experience, transparency, and governance for healthcare providers, payers, and other healthcare organizations. The company was founded by Michael D. Hays in 1981 and is headquartered in Lincoln, NE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NRC Health reports mixed Q4 2022 results amidst growth opportunities

NRC Health faced challenges in operating income and tax rates in Q4 2022 but demonstrated strength in core offering growth and client relationships.
The company's focus on humanized healthcare and capital allocation for innovation present opportunities for future growth and competitiveness.
Strategic adjustments post the Canadian location closure and efficient capital expenditure management will be key to overcoming challenges and seizing opportunities.
Overall, NRC Health's performance in Q4 2022 reflects a mix of challenges, strengths, and opportunities that will shape its future trajectory in the healthcare industry.

NRC Health reports Q1 revenue decline, focuses on healthcare humanization

NRC Health faced revenue and operating income declines in Q1 2023, attributed to a location closure and increased marketing expenses.
Despite challenges, the company's recognition as a top workplace and clear capital allocation priorities showcase strengths and strategic focus.
Opportunities lie in leveraging healthcare humanization and patient insights for future growth and exploring new markets for revenue diversification.

National Research Corp reports sales surge amidst revenue decline

NRC's Q2 2023 earnings call highlighted mixed financial performance with strong sales growth but revenue and income declines. The company's strategic focus on the Human Understanding Program and cost alignment presents opportunities for future growth and efficiency.

National Research Corp (NRC) reports mixed Q3 results, eyes growth opportunities

National Research Corp (NRC) navigated Q3 2023 with a focus on revenue growth acceleration and margin expansion. Despite challenges in operating income, the company's strategic initiatives and strong balance sheet position it well for future growth opportunities.

National Research Corp (NRC) reports mixed Q4 results, eyes growth opportunities

National Research Corp (NRC) navigated mixed financial results in Q4 2023, with a focus on strategic realignment to meet client demands and achieve growth. While facing challenges such as revenue decline and profitability pressures, the company remains committed to innovation and long-term sustainability. Future opportunities lie in expanding market reach, launching new products, and enhancing operational efficiency.

National Research Corp (NRC) posts solid Q1 results, eyes tech-driven growth

National Research Corp (NRC) reported solid Q1 2024 performance, focusing on technology-driven healthcare insights and strategic initiatives to drive growth and value creation for investors.
The company's emphasis on innovation, expanding the total addressable market, and enhancing client interactions underscores their commitment to delivering actionable insights and sustainable financial results.
With a strong financial foundation, NRC is well-positioned to navigate challenges, capitalize on opportunities, and drive continued growth through investments in technology, sales, and product development.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

National Research (NRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: National Research (NRC) Q2 Earnings Expected to Decline

AngioDynamics

Ensign Group

Genomic Health

Ionis Pharma

Masimo

Osiris Therapeutics

These healthcare stocks will help you not only profit from the growing demand, but also the growing tech in the healthcare sector.

7 A-Rated Healthcare Stocks for Industry Expansion

National Research Corporation (NRC) CEO Michael Hays on Q1 2019 Results - Earnings Call Transcript

News for National Research Corp Stock (NRC)